Dr. Timothy Jinks is the Head of Drug Resistant Infections Priority Program leading Wellcome Trust’s strategic plan to address antimicrobial resistance. He also serves as Wellcome Trust’s Non-Executive Director of the antiviral drug development company Reviral Ltd. In his preceding role in Wellcome’s Innovations Division, he was responsible for a portfolio of over a dozen early stage product development projects covering therapeutics, diagnostic and devices spanning across therapeutic areas such as infectious diseases and oncology. Prior to joining the Trust in 2012 he has over a decade of industry experience, most recently as a consultant providing business development, licensing and commercial research services.
